Business Description
Cingulate Inc
NAICS : 325412
SIC : 2834
ISIN : US17248W2044
Description
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.02 | |||||
| Equity-to-Asset | -1.97 | |||||
| Debt-to-Equity | -0.51 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -29.2 | |||||
| 3-Year EPS without NRI Growth Rate | -27 | |||||
| 3-Year FCF Growth Rate | -9.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.1 | |||||
| 9-Day RSI | 40.73 | |||||
| 14-Day RSI | 36.62 | |||||
| 6-1 Month Momentum % | -87.15 | |||||
| 12-1 Month Momentum % | -95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.06 | |||||
| Quick Ratio | 0.06 | |||||
| Cash Ratio | 0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27.4 | |||||
| Shareholder Yield % | -40.6 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -354.91 | |||||
| ROIC % | -263.81 | |||||
| ROC (Joel Greenblatt) % | -656.94 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.38 | |||||
| EV-to-Forward-EBIT | 0.46 | |||||
| EV-to-EBITDA | -0.38 | |||||
| EV-to-FCF | -0.57 | |||||
| Earnings Yield (Greenblatt) % | -263.16 | |||||
| FCF Yield % | -283.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CING
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cingulate Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -30.34 | ||
| Beta | 0 | ||
| Volatility % | 102.69 | ||
| 14-Day RSI | 36.62 | ||
| 14-Day ATR ($) | 0.09655 | ||
| 20-Day SMA ($) | 0.939459 | ||
| 12-1 Month Momentum % | -95 | ||
| 52-Week Range ($) | 0.75 - 23.4 | ||
| Shares Outstanding (Mil) | 6.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cingulate Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cingulate Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cingulate Inc Frequently Asked Questions
What is Cingulate Inc(CING)'s stock price today?
The current price of CING is $0.88. The 52 week high of CING is $23.40 and 52 week low is $0.75.
When is next earnings date of Cingulate Inc(CING)?
The next earnings date of Cingulate Inc(CING) is .
Does Cingulate Inc(CING) pay dividends? If so, how much?
Cingulate Inc(CING) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers